Reolysin is an oncolytic virus commercialized by Oncolytics Biotech, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

Treovir has been granted Fast-Track status for development of G207 by the FDA. G207 also has orphan drug designations for gliomas and ependymomas, medulloblastomas and primitive neuroectodermal tumors ...